David Bikard Wins the 2026 Richard Lounsbery Award for Phage Research
French microbiologist David Bikard, Director of Research at the Institut Pasteur in Paris, has received the 2026 Richard Lounsbery Award, a major scientific distinction recognizing outstanding achievements in biology and medicine. Announced on October 27, 2026, during the Académie des sciences' awards ceremony, the distinction recognizes a body of research exploring the molecular interactions between bacteria and bacteriophages, the evolution of bacterial defense systems and the development of programmable genetic technologies.
Bikard leads the Synthetic Biology Unit within the Institut Pasteur's Genomes and Genetics laboratory. His research addresses a fundamental question in microbiology: how do bacteria defend themselves against viruses, and how can the molecular mechanisms involved in this evolutionary struggle be transformed into tools for biotechnology and medicine?
The award is particularly relevant to the bacteriophage research community because Bikard's work extends beyond the conventional use of phages to kill pathogenic bacteria. His laboratory investigates the genetic mechanisms that govern bacterial immunity, including CRISPR-Cas systems, and explores how phage-derived delivery platforms can be used to manipulate bacterial populations with unprecedented specificity. These investigations connect fundamental discoveries in microbial evolution with emerging approaches to antimicrobial resistance and microbiome engineering.
Understanding the Molecular Arms Race Between Bacteria and Bacteriophages
Bacteriophages are viruses that infect bacteria. Their interactions with bacterial hosts have driven the evolution of sophisticated molecular mechanisms on both sides. Bacteria have developed defense systems capable of recognizing and restricting invading genetic material, while phages have evolved countermeasures that allow them to evade or suppress these defenses.
CRISPR-Cas systems are among the best-known examples of bacterial antiviral immunity. In nature, these systems can use guide RNAs to recognize complementary sequences in invading genetic material, enabling Cas proteins to target and destroy the corresponding DNA or RNA, depending on the system. Their discovery as programmable defense mechanisms subsequently led to some of the most influential technologies in modern molecular biology.
Bikard's research investigates this evolutionary conflict at a deeper mechanistic level. Rather than studying bacteria and phages exclusively as pathogen and therapeutic agent, his team examines the genetic innovations that emerge from their continuous interactions. These investigations can reveal previously unknown defense systems, explain how phages overcome them and identify molecular components that can be repurposed for genetic engineering.
An important contribution came from a 2022 study published in Cell Host & Microbe, in which François Rousset, Florence Depardieu, David Bikard and colleagues identified regions enriched in antiviral defense systems within the genomes of certain phages and their satellites. Phage satellites are genetic elements that depend on helper phages for aspects of their propagation and can influence the outcome of interactions between different viruses and their bacterial hosts.
The researchers showed that these genetic elements can carry defense systems that protect bacteria against competing phages. This finding complicates the traditional picture of a simple evolutionary arms race between bacteria and viruses: mobile genetic elements can themselves carry mechanisms that reshape the balance of power between competing genetic entities.
One of the systems investigated was PARIS, short for Phage Anti-Restriction Induced System. Subsequent research published in Nature in 2024 by Bikard and collaborators helped explain how this defense system operates at the molecular level.
The system involves two proteins, AriA and AriB. When a phage counter-defense protein triggers the system, AriA undergoes a structural change that releases AriB, a nuclease capable of cleaving transfer RNA. This disrupts bacterial protein synthesis and inhibits phage propagation, potentially leading to growth arrest or death of the infected cell.
Understanding these mechanisms is important not only for evolutionary microbiology but also for biotechnology. Bacterial defense proteins, viral counter-defense mechanisms and their molecular interactions provide a growing source of components that researchers can adapt for genome engineering, genetic screening and the control of microbial populations.
Turning CRISPR-Cas Into Targeted Antimicrobial Technology
A defining feature of Bikard's research is the transition from understanding bacterial immunity to using it as an engineering tool.
In a landmark paper published in Nature Biotechnology in 2014, David Bikard and colleagues demonstrated how CRISPR-Cas nucleases could be delivered by bacteriophages to produce sequence-specific antimicrobial effects. The approach exploited the ability of CRISPR systems to recognize selected genetic sequences rather than relying exclusively on conventional antibiotics that act on broader bacterial targets.
The principle is straightforward but powerful. A phage-derived delivery vehicle introduces a genetic construct into a susceptible bacterium. The construct encodes a CRISPR system programmed with a guide sequence complementary to the intended target. Once expressed, the Cas nuclease can cut the targeted DNA, potentially killing the bacterium or eliminating a genetic element such as a plasmid carrying antibiotic resistance.
This strategy creates possibilities for selectively targeting harmful bacteria while limiting collateral effects on other members of a microbial community. Such precision could be valuable in settings where broad-spectrum antibiotics disrupt beneficial microbiota or where conventional treatments struggle against resistant pathogens.
Bikard is also a co-founder of Eligo Bioscience, a biotechnology company developing programmable antibacterial approaches targeting specific bacterial populations. The company's research illustrates how principles derived from phage biology and CRISPR engineering can be translated into potential therapeutic platforms.
Nevertheless, sequence-specific antimicrobials should not be confused with conventional phage therapy. In classic phage therapy, bacteriophages infect and replicate within susceptible bacteria, ultimately causing bacterial lysis. In CRISPR-based approaches, phages or phage-derived particles can instead serve as delivery vehicles for genetic machinery designed to kill bacteria or modify particular genes.
These technologies remain subject to their own challenges, including delivery efficiency, bacterial specificity, resistance mechanisms, safety and manufacturing. Their promise lies in expanding the range of possible antimicrobial strategies, not in eliminating the need for existing treatments.
Engineering Bacteria Directly Within the Gut Microbiome
One of the most striking extensions of this research programme is the possibility of modifying bacteria directly within their natural environment.
Traditional bacterial genetics generally requires researchers to isolate microorganisms, cultivate them in the laboratory, modify their genomes and then reintroduce them into an experimental system. This process can be difficult for bacteria that are challenging to culture and may disrupt the ecological interactions that determine their behavior in a complex microbial community.
In a study published in Nature in July 2024, Andreas K. Brödel, Loïc H. Charpenay, David Bikard and colleagues demonstrated an alternative approach using a phage-derived particle to deliver a base editor to Escherichia coli colonizing the mouse gut.
The researchers targeted a β-lactamase gene, which can contribute to resistance against β-lactam antibiotics. Following a single dose, the median editing efficiency reached 93% of the target bacterial population under the experimental conditions. Edited bacteria remained detectable in the gut for at least 42 days.
Importantly, the team designed the DNA delivery system to be non-replicative in recipient bacteria, reducing the risk that the genetic payload would be maintained and disseminated beyond its intended purpose. The researchers also investigated additional targets in E. coli and Klebsiella pneumoniae in vitro and demonstrated in situ editing of a gene involved in curli production in a pathogenic E. coli strain.
These results represent a significant experimental advance in microbiome engineering. Rather than attempting to eliminate every undesirable bacterium, researchers may eventually be able to modify specific bacterial functions while leaving much of the surrounding community intact.
The approach could support studies of microbial gene function and, potentially, the development of targeted therapies against bacterial traits associated with disease. However, the reported results were obtained in experimental systems, including mice, and do not establish that comparable interventions are safe or effective in humans.
A 2026 review co-authored by Amandine Maire, Raphaël Laurenceau, Nathalie Rolhion and David Bikard in Current Opinion in Microbiology further examines emerging strategies for genetic modification of gut bacteria in situ. It highlights the growing interest in phage-derived vectors, phagemids and other delivery systems for investigating microbial functions within their native ecosystems.
Why the Richard Lounsbery Award Matters
The Richard Lounsbery Award is a French-American scientific distinction administered in alternating years by the French Académie des sciences and the U.S. National Academy of Sciences. Established in 1978, the award recognizes outstanding achievements in biology and medicine while encouraging scientific exchange and collaboration between France and the United States.
Bikard's recognition highlights the importance of fundamental research that connects microbial evolution with technological innovation. His work does not focus on a single bacteriophage preparation or a single therapeutic application. Instead, it investigates the molecular principles that determine how bacteria and phages interact, how genetic defense systems function and how these systems can be adapted for new purposes.
This breadth is particularly valuable as antimicrobial resistance creates an urgent need for approaches that complement conventional antibiotics. Understanding bacterial immunity can reveal new molecular targets, while phage-derived delivery systems can help researchers direct genetic interventions toward selected bacterial populations.
The distinction also reflects the increasingly interdisciplinary nature of modern microbiology. Research at the interface of bacteriophages, synthetic biology, microbial genetics and computational analysis can produce discoveries that are relevant to several fields, from fundamental evolutionary biology to the development of precision antimicrobials.
However, recognition of scientific achievement should not be interpreted as evidence that all resulting technologies are ready for clinical use. The therapeutic applications of CRISPR-based antimicrobials and microbiome engineering still require substantial further development, including rigorous safety assessment and clinical validation.
The significance of Bikard's work lies in creating the scientific foundations on which such future technologies may be built.
Expanding the Frontiers of Phage Research
David Bikard's research illustrates why bacteriophages are important far beyond their role as natural bacterial predators. The evolutionary conflict between bacteria and viruses has generated an extraordinary diversity of molecular mechanisms, many of which are now becoming useful tools for biological research and engineering.
From uncovering the molecular architecture of bacterial defense systems to developing CRISPR-based antimicrobials and demonstrating targeted genetic modification of bacteria within the mouse gut, his work connects fundamental discoveries with ambitious technological applications.
The 2026 Richard Lounsbery Award provides recognition for this research trajectory and the broader scientific questions it addresses. For the bacteriophage community, it also highlights the importance of studying phages not only as potential treatments for bacterial infections but as sources of molecular innovation that can transform our ability to understand and control microbial systems.
As research into precision antimicrobials and microbiome engineering advances, the challenge will be to translate these discoveries into safe, effective and clinically meaningful interventions. The work emerging from Bikard's research programme offers a compelling example of how fundamental phage biology can contribute to that effort.
Sources :
PR[AI]RIE (October 27, 2026). Félicitations à David Bikard, lauréat du Grand Prix Richard Lounsbery 2026. Official announcement of the award and summary of Bikard's research.
https://www.prairie-psai.fr/2026/10/27/felicitations-a-david-bikard-laureat-du-grand-prix-richard-lounsbery-2026/
Académie des sciences (October 27, 2026). Cérémonie de remise des prix de l'Académie des sciences. Official announcement naming David Bikard as the 2026 Richard Lounsbery Award recipient.
https://fr.linkedin.com/posts/academie-des-sciences_en-direct-c%C3%A9r%C3%A9monie-de-remise-des-prix-activity-7520853185788411905-umjt
Richard Lounsbery Foundation. The Richard Lounsbery Award. Information about the award's purpose and French-American scientific exchange.
https://www.rlounsbery.org/lounsberyaward
Rousset F., Depardieu F., Miele S., Dowding J., Laval A.-L., Lieberman E., Garry D., Rocha E. P. C., Bernheim A. & Bikard D. (2022). Phages and their satellites encode hotspots of antiviral systems. Cell Host & Microbe, 30(5), 740–753.e5.
https://doi.org/10.1016/j.chom.2022.02.018
Wang C. et al. (2024). Architecture and activation mechanism of the bacterial PARIS defence system. Nature.
https://doi.org/10.1038/s41586-024-07772-8
Bikard D., Euler C. W., Jiang W., Nussenzweig P. M., Goldberg G. W., Duportet X., Fischetti V. A. & Marraffini L. A. (2014). Exploiting CRISPR-Cas nucleases to produce sequence-specific antimicrobials. Nature Biotechnology, 32, 1146–1150.
https://doi.org/10.1038/nbt.3043
Brödel A. K. et al. (2024). In situ targeted base editing of bacteria in the mouse gut. Nature, 632, 877–884.
https://doi.org/10.1038/s41586-024-07681-w
Maire A., Laurenceau R., Rolhion N. & Bikard D. (2026). In situ genetic modification of gut bacteria. Current Opinion in Microbiology, 92, 102766.
https://doi.org/10.1016/j.mib.2026.102766
The Rockefeller University. From Battle to Breakthrough: Genetic Innovations and Biotechnological Applications of the Phage-Bacteria Arms Race. Research overview and scientific biography of David Bikard.
https://www.rockefeller.edu/events-and-lectures/57508-title-tba-487/
.png){kind=logo}
Comments
Post a Comment